Compare Gilead Sciences, Inc. (GILD) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard Value Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $146.25 (market cap $182.40B), while Vanguard Value Index Fund ETF trades at $219.8 (market cap $262.40B). The key difference: Vanguard Value Index Fund ETF is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard Value Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard Value Index Fund ETF for 142 Days on average.
| GILD | VTV | |
|---|---|---|
Market Cap | $182.40B | $262.40B |
Volume | 4,469,821 | 3,293,281 |
Sector | Health | — |
52-Week High | $155.80 | $227.51 |
52-Week Low | $116.74 | $182.86 |
Typical Hold Time | 111 Days | 142 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Vanguard Value ETF (VTV) trades at $218.21, down 0.35% on the day amid a bearish technical signal. The ETF shows neutral momentum oscillators but bearish moving averages, with key support at $217 and resistance at $219. Recent institutional buying by QRG Capital Management and Blue Edge Capital reflects confidence in value strategies, while news highlights VTV's 2.3% dividend yield and outperformance versus growth ETFs in 2026.
VTV offers exposure to large-cap value stocks with a low 0.03% expense ratio, appealing for income and stability. Risks include prolonged underperformance versus growth sectors and market rotation sensitivity. Analyst sentiment is mixed, balancing dividend appeal against broader market trends. The ETF remains a core holding for value-focused portfolios amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
